Buying targeted dividend ETFs is easier than buying high-yield dividend stocks.
Dividend
stocks were red-hot last year as the über-volatile market sent
investors headlong into what has traditionally been the most stable
segment of the equity universe. And while it isn’t likely we’ll see
quite as much volatility in 2012 as we did in the final four months of
2011, powerful unknowns, such as Europe’s unresolved debt issues and
China’s economic slowdown, could put real pressure on global economic
growth — and by extension, the fate of the world’s equity markets. That
means we could be in for an extended period of volatility and more
capital inflows into the dividend space.
As investors, we can buy a
well-thought-out group of solid, high-profile dividend stocks to gain
exposure to the segment. But it’s easier to buy targeted dividend ETFs
that already contain baskets of the best — and highest-yielding —
dividend-paying securities.
The 5 Best ETFs to Invest for 2013 - iShares Dow Jones Select Dividend Index
The
iShares Dow Jones Select Dividend (ETF) (NYSE:DVY) is an ETF pegged to
the Dow Jones index bearing its name. This ETF really saw gains during
the final three months of 2011, perhaps the most volatile time for
stocks all last year. The fund surged 11% over that period, and that
gain came with a 3.44% annual yield (as of Jan. 13). DVY counts among
its top holdings such stellar corporate names as Lorillard (NYSE:LO),
Chevron (NYSE:CVX), Kimberly-Clark (NYSE:KMB) and McDonald’s (NYSE:MCD),
to name just a few. The fund’s expense ratio is only 0.40%, making the
cost of owning these high-end performers very attractive.
SPDR S&P International Dividend
International
stocks were by no means the best performers last year, but that didn’t
stop the SPDR S&P International Dividend (ETF) (NYSE:DWX) from
delivering a solid dividend yield of 4.02%. DWX’s expense ratio is
0.45%, just slightly higher than the domestic-equity focused DVY. For
this modest cost, you get diversified exposure to international dividend
stocks in income sectors such as telecommunications, utilities and
financials.
The 5 Best ETFs to Invest for 2013 - WisdomTree Equity Income Fund
WisdomTree
Equity Income Fund (NYSE:DHS) enjoyed a good year, and it performed
particularly well in the final quarter. The fund is up almost 8% over
the past three months, and that comes with an annual yield of 3.31%. Its
holdings are based on WisdomTree’s Equity Income Index, which reads
like a Who’s Who of dividend stalwarts. Companies such as AT&T
(NYSE:T), General Electric (NYSE:GE), Johnson & Johnson (NYSE:JNJ)
and Procter & Gamble (NYSE:PG) top the list of payout performers you
get when you own DHS. And at an expense ratio of just 0.38%, you get
these great companies on the cheap.
The 5 Best ETFs to Invest for 2013 - iShares S&P U.S. Preferred Stock Index Fund
The
iShares S&P U.S. Preferred Stock Index Fund (NYSE:PFF) is an ETF
that gives you exposure to preferred stocks. I like this fund primarily
because of its outstanding 6.99% yield, but I also like it because it
diversifies your income portfolio by owning the preferred shares of some
of the world’s best companies. HSBC Holdings (NYSE:HBC), General Motors
(NYSE:GM), Wells Fargo (NYSE:WFC) and many others have issued
high-yield preferred shares, and the easiest and cheapest way to own
these equities — at an expense ratio of just 0.48% — is to have PFF in
your portfolio.
The 5 Best ETFs to Invest for 2013 - Claymore/Zacks Multi-Asset Income Index
Clamymore/Zacks
Multi-Asset Income Index (ETF) (NYSE:CVY) is perhaps the most eclectic
fund of my five best ETFs for 2012. CVY has had a great run over the
past three months, vaulting nearly 6% while offering an annual yield of
5.42%. One huge reason to love CVY is that it contains a host of
different types of high-yield securities. In addition to domestic and
international stocks, the fund holds real estate investment trusts,
master limited partnerships, closed-end funds, Canadian royalty trusts
and traditional preferred stocks. Owning CVY gives you the best of the
best when it comes to income securities at a quite acceptable 0.78%
expense ratio
Top 5 Emerging Growth Stocks to Buy for January in 2012
If you have cash to invest this month, I highly recommend these five below. Here they are, in no particular order:
Taiwan-based Silicon Motion Technology (NASDAQ:SIMO) has its hand in lots of hot markets and is a big player in flash memory storage — flash memory cards, USB flash drives, card readers and solid-state hard drives. In fact, most of the NAND flash and next-generation flash products on the market — whether produced by Samsung (PINK:SSNLF), SanDisk (NASDAQ:SNDK), Toshiba, Micron (NASDAQ:MU) or Intel (NASDAQ:INTC) — are supported by Silicon Motion controllers. Silicon Motion also produces multimedia chips including embedded graphics processors, image processors and TV tuners. Lastly, it has been increasingly focused on controllers for smartphones, tablets and notebook PCs, as well as wireless transceivers for 4G LTE smartphones and tablets.
In the third quarter, Silicon Motion’s sales rose 25% to $63.2 million compared with $50.5 million in the second quarter. Looking forward, the analyst community is expecting annual fourth-quarter sales growth of 51% and 88.9% earnings growth. In the past three months, the analyst community has revised their consensus earnings estimate 32% higher — a phenomenon that typically precedes blowout earnings surprises.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Questor Pharmaceuticals (NASDAQ:QCOR) likes a challenge. As a specialist of difficult-to-treat central nervous system disorders, the company has been particularly successful with its multiple sclerosis treatment, H.P. Acthar Gel. The company also makes Doral, which is used for the treatment of insomnia. In the massive biotechnology industry, Questcor is top-notch in terms of earnings per share growth and return on equity.
For the fourth quarter, the analyst community is expecting 127.4% annual sales growth and 265.7% earnings growth of 38 cents per share. In the past three months, the analyst community has revised their consensus earnings estimate 32.6% higher. Typically, such positive analyst earnings revisions precede future earnings surprises.
Top 5 Emerging Growth Stocks to Buy for January in 2012 -Hansen Natural (NASDAQ:HANS) is the mastermind behind Monster, a dominant energy drink in the U.S. Looking at a can of Monster Energy drink, the flashy staple of sleep-deprived college students, one wouldn’t think that the company’s humble beginnings stem back to just one father and three sons working with a juicer in Southern California. In fact, although Hansen sells supercharged drinks like Monster and Java Monster, most of its drink roster is actually very wholesome. For example, it has 30 real fruit and spice soda flavors, a number of immune system-boosting drinks, vitamin waters and an array of teas and lemonades.
In recent quarters, Hansen Natural has reported “monster” sales and profit growth. Third-quarter sales jumped 24% from $381.5 million last year to $474.7 million this quarter. Over the same period, net income also rose 24% to $82.4 million, or 88 cents per share. Plus, speculation is heating up that Monster might be an acquisition target by Red Bull or one of the major soft drink companies. With Red Bull’s recent decision to pull out of NASCAR as a sponsor, a “monster” acquisition might be just what the energy drink maker needs to capture additional U.S. market share.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is familiar pharmaceutical company I once discussed in the Top 5 Emerging Growth Stocks for December. Spectrum specializes in oncology — the treatment of cancer — and currently has two cancer treatments on the market: Fusilev, a treatment for advanced colon cancer, and Zevalin, a treatment for a type of lymphoma.
But what really excites me about this company is what it has in its pipeline: Spectrum has more than 10 drugs in either late-stage development or development! This includes Apaziquone, a treatment for bladder cancer, Belinostat, another lymphoma treatment and Ozarelix, a treatment of prostate cancer. This is a midsize biotechnology company already at the top of the industry — in terms of return on equity — and is about to experience blowout growth.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) has two flagship drugs — Xyrem, the only narcolepsy treatment approved by the World Anti-Doping Agency, and Luvox CR, its obsessive compulsive disorder treatment. But there are a number of exciting developments on the near horizon, including Jazz’s massive buyout of Dublin-based Azur Pharma Ltd., which should close within the next couple of weeks, and the company’s subsequent moving of its headquarters to Dublin. After the move, Jazz will be able to take advantage of Ireland’s competitive tax rate.
The company’s sales climbed 63.3% and earnings surged 115.6% in the third quarter, and for the fourth quarter, the analyst community is expecting 54% annual sales growth and 70.5% earnings growth. Jazz Pharmaceuticals is flush with cash and recently prepaid $33 million in long-term debt, and I’m excited to see how developments play out in the company’s next earnings release. Also, despite those who might think that Jazz Pharma’s bullish run looks tapped out, I remain optimistic.
Taiwan-based Silicon Motion Technology (NASDAQ:SIMO) has its hand in lots of hot markets and is a big player in flash memory storage — flash memory cards, USB flash drives, card readers and solid-state hard drives. In fact, most of the NAND flash and next-generation flash products on the market — whether produced by Samsung (PINK:SSNLF), SanDisk (NASDAQ:SNDK), Toshiba, Micron (NASDAQ:MU) or Intel (NASDAQ:INTC) — are supported by Silicon Motion controllers. Silicon Motion also produces multimedia chips including embedded graphics processors, image processors and TV tuners. Lastly, it has been increasingly focused on controllers for smartphones, tablets and notebook PCs, as well as wireless transceivers for 4G LTE smartphones and tablets.
In the third quarter, Silicon Motion’s sales rose 25% to $63.2 million compared with $50.5 million in the second quarter. Looking forward, the analyst community is expecting annual fourth-quarter sales growth of 51% and 88.9% earnings growth. In the past three months, the analyst community has revised their consensus earnings estimate 32% higher — a phenomenon that typically precedes blowout earnings surprises.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Questor Pharmaceuticals (NASDAQ:QCOR) likes a challenge. As a specialist of difficult-to-treat central nervous system disorders, the company has been particularly successful with its multiple sclerosis treatment, H.P. Acthar Gel. The company also makes Doral, which is used for the treatment of insomnia. In the massive biotechnology industry, Questcor is top-notch in terms of earnings per share growth and return on equity.
For the fourth quarter, the analyst community is expecting 127.4% annual sales growth and 265.7% earnings growth of 38 cents per share. In the past three months, the analyst community has revised their consensus earnings estimate 32.6% higher. Typically, such positive analyst earnings revisions precede future earnings surprises.
Top 5 Emerging Growth Stocks to Buy for January in 2012 -Hansen Natural (NASDAQ:HANS) is the mastermind behind Monster, a dominant energy drink in the U.S. Looking at a can of Monster Energy drink, the flashy staple of sleep-deprived college students, one wouldn’t think that the company’s humble beginnings stem back to just one father and three sons working with a juicer in Southern California. In fact, although Hansen sells supercharged drinks like Monster and Java Monster, most of its drink roster is actually very wholesome. For example, it has 30 real fruit and spice soda flavors, a number of immune system-boosting drinks, vitamin waters and an array of teas and lemonades.
In recent quarters, Hansen Natural has reported “monster” sales and profit growth. Third-quarter sales jumped 24% from $381.5 million last year to $474.7 million this quarter. Over the same period, net income also rose 24% to $82.4 million, or 88 cents per share. Plus, speculation is heating up that Monster might be an acquisition target by Red Bull or one of the major soft drink companies. With Red Bull’s recent decision to pull out of NASCAR as a sponsor, a “monster” acquisition might be just what the energy drink maker needs to capture additional U.S. market share.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is familiar pharmaceutical company I once discussed in the Top 5 Emerging Growth Stocks for December. Spectrum specializes in oncology — the treatment of cancer — and currently has two cancer treatments on the market: Fusilev, a treatment for advanced colon cancer, and Zevalin, a treatment for a type of lymphoma.
But what really excites me about this company is what it has in its pipeline: Spectrum has more than 10 drugs in either late-stage development or development! This includes Apaziquone, a treatment for bladder cancer, Belinostat, another lymphoma treatment and Ozarelix, a treatment of prostate cancer. This is a midsize biotechnology company already at the top of the industry — in terms of return on equity — and is about to experience blowout growth.
Top 5 Emerging Growth Stocks to Buy for January in 2012 - Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) has two flagship drugs — Xyrem, the only narcolepsy treatment approved by the World Anti-Doping Agency, and Luvox CR, its obsessive compulsive disorder treatment. But there are a number of exciting developments on the near horizon, including Jazz’s massive buyout of Dublin-based Azur Pharma Ltd., which should close within the next couple of weeks, and the company’s subsequent moving of its headquarters to Dublin. After the move, Jazz will be able to take advantage of Ireland’s competitive tax rate.
The company’s sales climbed 63.3% and earnings surged 115.6% in the third quarter, and for the fourth quarter, the analyst community is expecting 54% annual sales growth and 70.5% earnings growth. Jazz Pharmaceuticals is flush with cash and recently prepaid $33 million in long-term debt, and I’m excited to see how developments play out in the company’s next earnings release. Also, despite those who might think that Jazz Pharma’s bullish run looks tapped out, I remain optimistic.
Top 6 Stocks to Buy for February in 2012
With business inventories low, manufacturing up in December, an
increase in housing starts in November, consumer confidence up, and the
unemployment rate falling, the economy appears to be slowly improving.
But global issues and especially problems in the EU still plague the
market.
January started on a positive note with the Dow up over 3%, thus the familiar saying, “As goes the first week of the new year, so goes the month and so goes the year,” was frequently repeated. But on Jan. 26, the Dow and the S&P 500 executed “daily reversals,” and since then prices have been falling. All of our internal and sentiment indicators are overbought, and so the market could end the month on a negative yet still have delivered one of the most impressive bullish performances in years.
It is important for investors to focus on high-quality stocks that pay dividends and/or have a history of regular dividend increases. Some also have stock buyback programs in place to use part of their cash and reduce the number of shares trading. Both strategies should have a positive long-term impact on the companies’ stocks.
Here are your top stocks to buy for February:
Earnings are estimated at $4.94 in 2011 and $5.58 in 2012. The dividend yield is 1.21%. This stock is rated a “five-star strong buy” by S&P with a 12-month target of $80.
S&P has CVX rated a “five-star strong buy” with a target of $132. The consensus estimated earnings for 2011 are $14.02 and $13.65 for 2012. The annual dividend is $3.24, providing a yield of 3.12%. The company is expected to continue to increase dividends and is executing a share buyback program.
Top Stock to Buy #3 – H.J. Heinz Co. (HNZ)
H.J. Heinz Co. (NYSE:HNZ), a producer of a wide variety of food products, has a new, more aggressive corporate strategy. Acquisitions in “emerging markets” began two years ago, and in 2011 that new direction accounted for 16% of total sales. Earnings for FY 2011 were $3.06 and are estimated to be $3.30 in FY 2012. HNZ has a dividend yield of 3.71% and a history of increasing dividends. The fundamental target for HNZ is $60.
Technically the stock has double-bottomed at $48 and formed a neckline of resistance at $54.50. A recent buy signal from our proprietary indicator, the Collins-Bollinger Reversal (CBR), tells us to buy now for a breakout and run to $62.
Credit Suisse analysts consider UNH to be the best-positioned company in its field and look for earnings of $4.85 this year compared to $4.73 in 2011, and an increase to $5.60 in 2013. UNH has a dividend yield of 1.27%.
Technically the stock has consolidated in a broad cup. A break through $54 should produce a trading target of $62.
Top Stock to Buy #5 – Verizon Communications (VZ)
Verizon Communications’ (NYSE:VZ) earnings are expected to grow to $2.50 next year, up from $2.23 in 2011, and strong operating margins and network quality are expected to attract customers to its 3G and 4G networks.
The communications sector has been one of the strongest in the closing months of 2011, and VZ has been a leader of the group. But the sector, and Verizon, may have run too far too fast. An increase in sellers and a short-term sell signal from its stochastic warn that a correction is likely.
Buy VZ on a pullback under $38 for a longer-term advance to the mid-$40s.
Top Stock to Buy #6 – Whole Foods Market (WFM)
Whole Foods Market (NASDAQ:WFM), the operator of the largest chain of natural food supermarkets in theUnited States, appears headed to new highs. Sales are expected to increase by 15% in 2012, and earnings are estimated to increase to $2.27 from $1.93 in 2011 and $1.43 in 2010. The adoption of a new price strategy, more lower-priced offerings, and an expansion plan are expected to lead to better-than-average industry growth. The dividend will likely be increased from the current 56 cents per share, and the repurchase of shares is expected.
Technically WFM has been in a powerful bull channel for over a year, and while there is no reason to expect a change, the stock is currently in a correction and will most likely hold at the lower support line of the channel at the 50-day moving average at $70 where it should be bought. The target for a trade is $80 by the end of March. Longer-term buyers should expect continued growth and higher prices.
January started on a positive note with the Dow up over 3%, thus the familiar saying, “As goes the first week of the new year, so goes the month and so goes the year,” was frequently repeated. But on Jan. 26, the Dow and the S&P 500 executed “daily reversals,” and since then prices have been falling. All of our internal and sentiment indicators are overbought, and so the market could end the month on a negative yet still have delivered one of the most impressive bullish performances in years.
It is important for investors to focus on high-quality stocks that pay dividends and/or have a history of regular dividend increases. Some also have stock buyback programs in place to use part of their cash and reduce the number of shares trading. Both strategies should have a positive long-term impact on the companies’ stocks.
Here are your top stocks to buy for February:
Top Stock to Buy #1 – Barrick Gold Corp. (ABX)
Barrick Gold Corp. (NYSE:ABX), an acquirer, explorer and developer of gold, copper, silver and zinc, is charted using monthly rather than daily data. This long-term chart clearly shows a bullish cup-and-handle formation. But for the stock to break out it must close above $55. If ABX breaks $55, look for a major rally to $75 to $80.Earnings are estimated at $4.94 in 2011 and $5.58 in 2012. The dividend yield is 1.21%. This stock is rated a “five-star strong buy” by S&P with a 12-month target of $80.
Top Stock to Buy #2 – Chevron Corp. (CVX)
Chevron Corp. (NYSE:CVX) primarily engages in exploration, refining, transportation and storage of crude oil and natural gas. The stock has formed a neckline at $110 after establishing a double-bottom. The overall pattern is an inverse head-and-shoulders — a very bullish development. All that is required to trigger a strong buy is for the stock to close above the neckline. This is a huge bullish formation with a technical target of $132.S&P has CVX rated a “five-star strong buy” with a target of $132. The consensus estimated earnings for 2011 are $14.02 and $13.65 for 2012. The annual dividend is $3.24, providing a yield of 3.12%. The company is expected to continue to increase dividends and is executing a share buyback program.
Top Stock to Buy #3 – H.J. Heinz Co. (HNZ)
H.J. Heinz Co. (NYSE:HNZ), a producer of a wide variety of food products, has a new, more aggressive corporate strategy. Acquisitions in “emerging markets” began two years ago, and in 2011 that new direction accounted for 16% of total sales. Earnings for FY 2011 were $3.06 and are estimated to be $3.30 in FY 2012. HNZ has a dividend yield of 3.71% and a history of increasing dividends. The fundamental target for HNZ is $60.
Technically the stock has double-bottomed at $48 and formed a neckline of resistance at $54.50. A recent buy signal from our proprietary indicator, the Collins-Bollinger Reversal (CBR), tells us to buy now for a breakout and run to $62.
Top Stock to Buy #4 – United Health Group (UNH)
The diversified United Health Group (NYSE:UNH) provides health care programs and retirement plans, has a life sciences group, and provides health plans to physicians, clinical services, etc.Credit Suisse analysts consider UNH to be the best-positioned company in its field and look for earnings of $4.85 this year compared to $4.73 in 2011, and an increase to $5.60 in 2013. UNH has a dividend yield of 1.27%.
Technically the stock has consolidated in a broad cup. A break through $54 should produce a trading target of $62.
Top Stock to Buy #5 – Verizon Communications (VZ)
Verizon Communications’ (NYSE:VZ) earnings are expected to grow to $2.50 next year, up from $2.23 in 2011, and strong operating margins and network quality are expected to attract customers to its 3G and 4G networks.
The communications sector has been one of the strongest in the closing months of 2011, and VZ has been a leader of the group. But the sector, and Verizon, may have run too far too fast. An increase in sellers and a short-term sell signal from its stochastic warn that a correction is likely.
Buy VZ on a pullback under $38 for a longer-term advance to the mid-$40s.
Top Stock to Buy #6 – Whole Foods Market (WFM)
Whole Foods Market (NASDAQ:WFM), the operator of the largest chain of natural food supermarkets in theUnited States, appears headed to new highs. Sales are expected to increase by 15% in 2012, and earnings are estimated to increase to $2.27 from $1.93 in 2011 and $1.43 in 2010. The adoption of a new price strategy, more lower-priced offerings, and an expansion plan are expected to lead to better-than-average industry growth. The dividend will likely be increased from the current 56 cents per share, and the repurchase of shares is expected.
Technically WFM has been in a powerful bull channel for over a year, and while there is no reason to expect a change, the stock is currently in a correction and will most likely hold at the lower support line of the channel at the 50-day moving average at $70 where it should be bought. The target for a trade is $80 by the end of March. Longer-term buyers should expect continued growth and higher prices.
3 Undervalued Tech Stocks to Buy in 2012
When investors see the words “undervalued tech stocks,” the first
companies that jump to mind are probably the mega-cap giants like Cisco (NASDAQ:CSCO) and Microsoft
(NASDAQ:MSFT). The large-cap space certainly has more than its share of
cheap tech stocks, but a look into mid- and small-cap territory reveals
other, less talked-about opportunities. Computer Sciences (NYSE:CSC), Lexmark International (NYSE:LXK), and China Digital TV (NYSE:STV), are three such stocks that deserve more attention than they receive.
3 Undervalued Tech Stocks to Buy in 2012 - Computer Sciences
Shares of CSC, an IT-outsourcing company, have been pummeled from a February high above $56 to $37.20 on Wednesday. The stock has been hit by less-than-stellar earnings results and concerns that the U.S. government’s perilous fiscal situation will weigh on the 39% of CSC’s business that comes from federal contracts. That’s undoubtedly a legitimate worry, but also one that is well-known at this point. At 7.3 times 2012 estimates (and a price-to-earnings-to-growth ratio of 0.9) and a share price sitting at 0.8 times book value, it appears that the bad news is fully discounted in the stock. Two other key points regarding CSC: first, the stock yields 2.2% – much better than you’ll find with the average large-cap tech stock. Second, the company is cash-rich and is frequently mentioned as a target of a buyout. Betting on a takeover is always a dicey proposition, but CSC offers investors a solid risk-reward tradeoff even without the benefit of a buyout.
Keep in mind: The last time CSC’s P/E was at this level, the stock traded up 25% in less than two months.
3 Undervalued Tech Stocks to Buy in 2012 - Lexmark International
A maker of printers, ink, and imaging products, Lexmark has seen its shares come under heavy selling pressure since late 2010 – a trend that wasn’t helped by its May earnings miss. While the printing business is indeed in gradual decline, it may finally be time to say “enough is enough” regarding the downturn in Lexmark’s share price. After hitting a high above $47 in mid-October, the stock now stands at $28.62. At this level, the stock trades at forward P/E of less than 7x, and removing the net cash of $7 a share (about a quarter of its market cap) on its balance sheet brings the P/E below 5.5x. A low P/E can be a trap when growth is slowing, of course, but the company’s core ink business continues to generate substantial free cash flow. And like CSC, Lexmark has the added benefit of being a strong candidate for an eventual takeover.
Keep in mind: The recent selloff has driven LXK’s valuation to its lowest level in history.
3 Undervalued Tech Stocks to Buy in 2012 - China Digital TV
The smallest of the three companies discussed here, China Digital could offer big potential to patient investors. The company makes smart cards that allow the conversion of an analog signal to digital. A boring business perhaps, but consider that China is the world’s largest TV market with 377 million viewing households. Of these, 187 million have cable and only 90 million currently have a digital signal. This adds up to a stellar growth opportunity for a company with no debt and over 70% of its market cap accounted for by the $214 million of cash on its balance sheet. The stock trades for less than 7x 2012 earnings estimates and a PEG of just over 0.4. Chinese stocks are not without risk, as 2011 has taught us, but patient investors who tune into STV may be in for quite a show.
Keep in Mind: Like LXK, CSC trades at an all-time low P/E.
Technology investing has been no picnic for investors thus far in 2011, but these stocks provide a compelling margin of safety in the event of further volatility in the months ahead.
3 Undervalued Tech Stocks to Buy in 2012 - Computer Sciences
Shares of CSC, an IT-outsourcing company, have been pummeled from a February high above $56 to $37.20 on Wednesday. The stock has been hit by less-than-stellar earnings results and concerns that the U.S. government’s perilous fiscal situation will weigh on the 39% of CSC’s business that comes from federal contracts. That’s undoubtedly a legitimate worry, but also one that is well-known at this point. At 7.3 times 2012 estimates (and a price-to-earnings-to-growth ratio of 0.9) and a share price sitting at 0.8 times book value, it appears that the bad news is fully discounted in the stock. Two other key points regarding CSC: first, the stock yields 2.2% – much better than you’ll find with the average large-cap tech stock. Second, the company is cash-rich and is frequently mentioned as a target of a buyout. Betting on a takeover is always a dicey proposition, but CSC offers investors a solid risk-reward tradeoff even without the benefit of a buyout.
Keep in mind: The last time CSC’s P/E was at this level, the stock traded up 25% in less than two months.
3 Undervalued Tech Stocks to Buy in 2012 - Lexmark International
A maker of printers, ink, and imaging products, Lexmark has seen its shares come under heavy selling pressure since late 2010 – a trend that wasn’t helped by its May earnings miss. While the printing business is indeed in gradual decline, it may finally be time to say “enough is enough” regarding the downturn in Lexmark’s share price. After hitting a high above $47 in mid-October, the stock now stands at $28.62. At this level, the stock trades at forward P/E of less than 7x, and removing the net cash of $7 a share (about a quarter of its market cap) on its balance sheet brings the P/E below 5.5x. A low P/E can be a trap when growth is slowing, of course, but the company’s core ink business continues to generate substantial free cash flow. And like CSC, Lexmark has the added benefit of being a strong candidate for an eventual takeover.
Keep in mind: The recent selloff has driven LXK’s valuation to its lowest level in history.
3 Undervalued Tech Stocks to Buy in 2012 - China Digital TV
The smallest of the three companies discussed here, China Digital could offer big potential to patient investors. The company makes smart cards that allow the conversion of an analog signal to digital. A boring business perhaps, but consider that China is the world’s largest TV market with 377 million viewing households. Of these, 187 million have cable and only 90 million currently have a digital signal. This adds up to a stellar growth opportunity for a company with no debt and over 70% of its market cap accounted for by the $214 million of cash on its balance sheet. The stock trades for less than 7x 2012 earnings estimates and a PEG of just over 0.4. Chinese stocks are not without risk, as 2011 has taught us, but patient investors who tune into STV may be in for quite a show.
Keep in Mind: Like LXK, CSC trades at an all-time low P/E.
Technology investing has been no picnic for investors thus far in 2011, but these stocks provide a compelling margin of safety in the event of further volatility in the months ahead.
Subscribe to:
Posts (Atom)